Program Option Sample Clauses

Program Option. On the Option Exercise Date for the exercise of the SMA Program Option, the restrictive covenant Section 11.1.4.2 (SMA Restrictive Covenant) shall automatically terminate, and thereby Genzyme will cease to be prohibited from exercising its worldwide license rights under Section 11.1.3 (License Grant to SMA Licensed Program) with respect to the SMA Agreement Program.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Program Option. Please choose which version of the program you would like to reserve. Smartphone App Only Printed Program (includes Smartphone App access)
Sample 1Sample 2
Program Option. Initial the program option that you need: Full-Time Drop-in
Sample 1
Program Option. (Choose 1) Smartphone App Only Printed Program (includes Smartphone App access) MEETING GIFT: (Choose 1) Bag/Brief Padfolio None REGISTRATION FEES: All Meeting Attendees/Participants Are Required To Register. PAYMENT MUST BE MADE/PROCESSED TO BE OFFICIALLY REGISTERED. A receipt will be sent via email. Postmarked, e-mailed, or faxed BEFORE October 1 Postmarked, e-mailed, or faxed ON or AFTER October 1 ASC Member: $150.00 ASC Member: $200.00 Non-Member: $190.00 Non-Member: $240.00 ASC Student Member: $50.00 ASC Student Member: $60.00 Student Non-Member: $100.00 Student Non-Member: $110.00 THE LAST DAY TO PRE-REGISTER IS OCTOBER 30TH 2023. OPTIONAL SPECIAL EVENTS Division on Corrections and Sentencing Annual Business / Awards Breakfast Meeting (150 limit) Thursday, Nov. 16th, 7:30am – 9:20am (Room TBD) Students: $5.00 Non-Students: $15.00 Division of Feminist Criminology Social (150 limit) Wednesday, Nov. 15th, 8:00pm – 10:00pm (Offsite: TBD) Students: $10.00 Non-Students: $20.00 Division of International Criminology Awards Presentation and Luncheon (100 limit) Friday, Nov. 17th, 12:00pm – 1:30pm (Offsite: Maggiano’s Little Italy) Students: $30.00 Non-Students: $50.00 Division on People of Color & Crime Awards Presentation and Luncheon (75 limit) Thursday, Nov. 16th, 12:30pm – 2:00pm (Offsite: Maggiano’s Little Italy) All Students: $25.00 (DPCC Member or not) DPCC Members: $35.00 Non-DPCC Members: $40.00 Refund Policy: I understand that advance registration fees will be refunded for cancellations received up to September 30th. No refunds will be made on cancellations received after this date. Initial here: PAYMENT: To pay by credit card, if at all possible, we recommend you use our online system (the account should be in attendee’s name). Otherwise, please select below (DO NOT include credit card information on this form or in an email): □ Check or money order enclosed, made out to American Society of Criminology. (U.S. FUNDS ONLY). A service charge will be assessed for all returned checks. □ I will give credit card information over the phone. Please call at We accept Visa, MasterCard, American Express, Discover. □ I need a secure credit card payment link (paying on behalf of someone else) emailed to: Introduction CODE OF CONDUCT As an organization, we uphold our Code of Ethics (xxxxx://xxx00.xxx/about-asc/core-documents/#toggle-id-6). Section II #5 of the Code states, “In their professional activities, ASC members are committed to enhancing the general well-...
Sample 1
Program Option. Please choose which version of the program you would like to reserve. If you have not used the smartphone app before, we urge you to choose the printed program to ensure enough books are ordered. If you choose “App Only,” there will not be a printed program for you. However, you may check with us at the end of the meeting regarding the availability, if any, of leftover printed programs. Smartphone App Only Printed Program (includes Smartphone App access)
Sample 1
Program Option. (a) In consideration for entering into the Operative Documents to which both Exelixis and Symphony Evolution are parties, Symphony Evolution hereby grants Exelixis an exclusive option (the “Program Option”) to purchase the rights to one Program at any time during the period (the “Program Option Period”) after Exelixis has, by itself or through its subcontractor(s), [ * ] and before the earlier of (A) the termination of the Term, and (B) the eighteenth (18th) month anniversary of the Closing Date, in accordance with this Section 11.1.
Sample 1
Program Option. (a) In consideration for entering into the Operative Documents to which both Dynavax and Symphony Dynamo are parties, Symphony Dynamo hereby grants Dynavax an exclusive option (the “Program Option”) to purchase the rights to either the Hepatitis B Program or the Hepatitis C Program (but not both) at any time during the period beginning on the Closing Date and terminating on the first (1st) anniversary of the Closing Date (the “Program Option Period”); provided, however, that Dynavax shall not exercise the Program Option with respect to the Hepatitis C Program until such time as Dynavax shall have either: (i) [ * ]; or (ii) [ * ].
Sample 1
AutoNDA by SimpleDocs
Program Option 
Sample 1

Related to Program Option

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to commercialize a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries. If Novartis commercializes a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries, Novartis will be deemed to satisfy all diligence obligations with respect to such Profile.

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Royalty Term On a country-by-country and Licensed Product-by-Licensed Product basis, royalty payments in the Territory shall commence upon the first commercial sale of such Licensed Product, whether such sale is to a Public Purchaser, Governmental Authority or private entity or person and whether such sale is made under an EUA or Key Approval, in such country in the Territory and will terminate upon the later of: (a) the expiration, invalidation or abandonment date of the last Valid Claim of the Patents in the country of sale or manufacture of such Licensed Product in the Territory or (b) expiration of regulatory exclusivity of such Licensed Product in such country of sale in the Territory (the “Royalty Term”).

Time is Money Join Law Insider Premium to draft better contracts faster.